Saturday 17 October 2026
Export GOVX’s income statement to Excel — free account
GeoVax Labs Inc.
GOVX Healthcare Biotechnology
GeoVax Labs Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 million, down 37.1% from fiscal 2024. In the quarter to June 2026, revenue grew 183.4%, EPS grew 88.9% and free cash flow grew 15.8%, each against the same quarter a year earlier.
0.23
0.03
−11.54%
Follow GOVX
GeoVax Labs Inc. (GOVX) P/E ratio
GeoVax Labs Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 35.8× (May 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2025 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.0× | — |
| 30 more quarters | Free account |
Against its own ten years
Low 0.0×
High 35.8×
Ten-year median
0.0×
Current reading's percentile
87
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SLXN Silexion Therapeutics Corp compare | n/m |
| VIVS VivoSim Labs, Inc. compare | n/m |
| XRTX XORTX Therapeutics Inc. compare | n/m |
| GOVX GeoVax Labs Inc. | n/m |
| HCWB HCW Biologics Inc. compare | n/m |
| ELAB PMGC Holdings Inc. compare | n/m |
| EIGRQ Eiger BioPharmaceuticals, Inc. compare | n/m |
| AFMDQ Affimed N.V. compare | n/m |
| BIORQ Biora Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)